Thuja

FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant

Retrieved on: 
Thursday, November 17, 2022

FundaMental scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration.

Key Points: 
  • FundaMental scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration.
  • For more information, please visit: www.fundamentalpharma.com
    BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies.
  • BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.
  • Thuja Capital Management (Thuja Capital) manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, medtech and digital health.

KU Leuven spin-off AstriVax raises € 30 million seed capital to build vaccine platform

Retrieved on: 
Thursday, August 25, 2022

Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven.

Key Points: 
  • Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven.
  • Leuven, Belgium, 25 August 2022 Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs.
  • The company will also continue to build its highly innovative, first-in-class plug-and-play vaccine platform based on the ground-breaking work of co-founders Professor Johan Neyts and Kai Dallmeier, PhD, from the KU Leuven Rega Institute.
  • From 2005 to 2021, KU Leuven invested 21.7 million in its spin-off companies, and 1.46 billion of external capital was raised.